AstraZeneca wins US injunction blocking Apotex's Pulmicort generic
This article was originally published in Scrip
Executive Summary
AstraZeneca claims it has won an injunction from a US court that bars Apotex from selling a generic version of the branded asthma treatment Pulmicort Respules (budesonide inhalation suspension, or BIS). No firm currently markets generic Pulmicort in the US.